Zydus Lifesciences announced that it has obtained approval from the USFDA to sell a generic medication for the treatment of postherpetic neuralgia. The company has received the final nod from the US Food and Drug Administration (USFDA) to produce and distribute Gabapentin tablets in strengths of 300 mg and 600 mg, as stated in a regulatory filing by Zydus Lifesciences.
India News: Zydus Lifesciences has received approval from the US Food and Drug Administration (USFDA) to market a generic medication to manage postherpetic neuralgia. Read more.
/PRNewswire/ The "Digital Dose Inhaler Market Size, Share & Trends Analysis Report By Product (MDI, DPI), By Indication (Asthma, COPD), By Type (Branded.
Global Digital Dose Inhaler Market Primed for Remarkable Growth, Forecasted to Reach $53 32 Billion by 2030 itnewsonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnewsonline.com Daily Mail and Mail on Sunday newspapers.